The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis
Emma C. Derrett‐Smith, Kristina E N Clark, Xu Shiwen et al. · Arthritis Research & Therapy · 2021
BACKGROUND: The TβRII∆k-fib transgenic (TG) mouse model of scleroderma replicates key fibrotic and vasculopathic complications of systemic sclerosis through fibroblast-directed upregulation of TGFβ signalling. We have examined peroxisome proliferator-activated receptor (PPAR) pathway perturbation in this model and explored the impact of the pan-PPAR agonist lanifibranor on the cardiorespiratory phenotype. METHODS: PPAR pathway gene and protein expression differences from TG and WT sex-matched littermate mice were determined at baseline and following administration of one of two doses of lanifibranor (30 mg/kg or 100 mg/kg) or vehicle administered by daily oral gavage up to 4 weeks. The prevention of bleomycin-induced lung fibrosis and SU5416-induced pulmonary hypertension by lanifibranor was explored. RESULTS: Gene expression data were consistent with the downregulation of the PPAR pathway in the TβRII∆k-fib mouse model. TG mice treated with high-dose lanifibranor demonstrated significant protection from lung fibrosis after bleomycin and from right ventricular hypertrophy following induction of pulmonary hypertension by SU5416, despite no significant change in right ventricular systolic pressure. CONCLUSIONS: In the TβRII∆k-fib mouse strain, treatment with 100 mg/kg lanifibranor reduces the development of lung fibrosis and right ventricular hypertrophy induced by bleomycin or SU5416, respectively. Reduced PPAR activity may contribute to the exaggerated fibroproliferative response to tissue injury in this transgenic model of scleroderma and its pulmonary complications.
Cited by 26 works. doi:10.1186/s13075-021-02592-x Open-access PDF
Authors
- Emma C. Derrett‐Smith
- Kristina E N Clark
- David Abraham
- Rachel K. Hoyles
- Olivier Lacombe
- Pierre Broqua
- Jean‐Louis Junien
- Voon Hong Ong
- Christopher P. Denton
References
- Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes
- Simple method of estimating severity of pulmonary fibrosis on a numerical scale.
- Prediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis
- Fibroblast-specific Expression of a Kinase-deficient Type II Transforming Growth Factor β (TGFβ) Receptor Leads to Paradoxical Activation of TGFβ Signaling Pathways with Fibrosis in Transgenic Mice
- Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities
- PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation
- Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
- PPARγ Activation: A Potential Treatment For Pulmonary Hypertension
- PPARβ/δ: Linking Metabolism to Regeneration
- Endothelial Injury in a Transforming Growth Factor β–Dependent Mouse Model of Scleroderma Induces Pulmonary Arterial Hypertension